Mode
Text Size
Log in / Sign up
Phase 4 N=54 Randomized Quadruple-blind Prevention

Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia

Idiopathic Scoliosis · Spondylolisthesis

Enrolled (actual)
54
Serious AEs
2.0%
Results posted
Nov 2015
Primary outcome: Primary: Morphine Equivalent Consumption (mg/kg) — 1.3; 1.36; 1.28; 1.275 mg/kg

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Ketamine (Drug); Normal Saline (Drug)
Age
Pediatric, Adult · 10+ yrs
Sex
All
Sponsor
Julia Finkel
Primary completion
May 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Morphine Equivalent Consumption (mg/kg)
1.3; 1.36; 1.28; 1.275; .89; .93
SECONDARY
Sedation Score
.73; .75; .62; .54; .38; .3
SECONDARY
Pain Score at Rest
3.9; 4.55; 4.53; 5.2; 3.6; 3.48
SECONDARY
Pain Score During Cough.
4.5; 5.1; 5.4; 5.45; 4.4; 3.7

Summary

The purpose of this study is to: 1. Establish whether ketamine can decrease opioid consumption and modulate the onset of opioid tolerance and prevent opioid-induced hyperalgesia in pediatric subjects, ages 10 years to 18 years, undergoing posterior spinal fusion and instrumentation.

Eligibility Criteria

Inclusion Criteria

  • The subject is 10 to 18 years of age
  • The subject's American Society of Anesthesiologists physical status is ASA 1, 2 or 3 (see appendix I)
  • The subject is scheduled for elective posterior spinal fusion and instrumentation.
  • The subject's parent/legally authorized guardian has given written informed consent to participate

Exclusion Criteria

  • The subject has a history or a family (parent or sibling) history of malignant hyperthermia
  • The subject is pregnant or nursing.
  • The subject has known significant renal disorders determined by medical history, physical examination or laboratory tests
  • The subject has a known or suspected allergy to morphine, remifentanil or ketamine
  • The subject is an ASA classification of 4 or greater (See Appendix I)
  • The subject is scheduled for a surgical sub-procedure (i.e. anterior spinal fusion)
  • The subject is unable to self-administer morphine using patient-controlled analgesia (PCA) pump
  • The subject had a recent opioid exposure (within 1 month of surgery)
  • The subject is obese (body mass index >30kg/m2)
  • The subject is planned for elective postoperative ventilation
  • The subject has a known ocular disease not permitting pupillometric examination
  • The subject has used any investigation products in the past 30 days
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01325493). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search